Continual Versus Occasional Blood Pressure (COOL-BP) in Remote Hypertension Management
Cuffless BP devices demonstrate promise in enhancing patient compliance and effectiveness in HTN management. Their integration into clinical practice could offer a more patient-friendly and reliable approach to BP monitoring, though more research is needed to establish their utility in large populations.
Authors
- Nicholas Chin
- Josep Sola (ORCID: https://orcid.org/0000-0002-2005-5733)
- David Zelle (ORCID: https://orcid.org/0000-0001-8193-5067)
- Christian Figueroa (ORCID: https://orcid.org/0000-0003-2692-284X)
- Christopher P. Cannon (ORCID: https://orcid.org/0000-0003-4596-2791)
- Daniel Gabovitch (ORCID: https://orcid.org/0009-0007-5854-4392)
- Benjamin M. Scirica (ORCID: https://orcid.org/0000-0002-7093-7048)
- Simin Lee
- Naomi D.L. Fisher (ORCID: https://orcid.org/0000-0003-1649-1441)
- Ozan Ünlü (ORCID: https://orcid.org/0000-0002-0106-5004)
- David Perruchoud
- Tiago P. Almeida (ORCID: https://orcid.org/0000-0001-5346-6937)
- Emma Collins (ORCID: https://orcid.org/0000-0003-3774-8189)
- Ryan Ruggiero
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Aktive Arc (Switzerland) (CH)
- Mass General Brigham (US)
Publication Details
- Journal
- American Journal of Hypertension
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1093/ajh/hpaf003
- Citations
- 4
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.55
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Brigham and Women's Hospital
- Biogen
- Alnylam Pharmaceuticals
- Harvard Business School
- CSL Behring
- Amarin Corporation
- ReCor Medical
- Amryt Pharma
- Novo Nordisk
- Esperion Therapeutics
- Daiichi Sankyo Europe